IBA (Louvain-La-Neuve), a specialist in proton therapy for cancer treatment, saw it’s stock rise from 7.3% to 23.90 euros. The Walloon company netted an American contract of 74 million euros in Florida for the construction and maintenance of a radiotherapy center.
KBC Securities analyst Jan De Kerpel maintains its ‘buy’-advice and targets a price of 27 euros. IBA recently missed out on some European contracts at expense of rival Varian. It is interesting to see that the Americans now chose IBA based on experience in proton therapy, while for hospitals in the UK and Denmark, the price was decisive.
The Walloon cancer specialist showed off last week with impressive results and an optimistic outlook. With proton therapy, cancer cells can be precisely irradiated up to a millimeter.
